Company intelligence / Profile preview
Galectin Therapeutics
Norcross, Georgia, United Statesgalectintherapeutics.com ↗
- Ownership
- Public · GALT
- Employees
- ~14
- Development stage
- Other
01
Overview
Galectin Therapeutics' lead candidate belapectin has shown statistically significant and clinically meaningful effects in MASH cirrhosis patients without esophageal varices in a Phase 2b trial. The ongoing NAVIGATE global clinical trial is a Phase 2b/3 study evaluating belapectin for MASH cirrhosis with portal hypertension; topline results are expected December 2024. Belapectin has also shown positive results in early-stage combination immunotherapy trials for metastatic melanoma and head and neck cancer.[5][9]
- Therapeutic areas
- OtherOncologyDermatologyMetabolic Disorders
- Modalities
- Small molecules (carbohydrate-based drugs/polysaccharide polymers)[1][7]
- Industry
- Biotech
02
Drug pipeline
5 assets4 more assets in the full pipeline.
03
Financials
- Market cap
- $196.6M
- Total revenue
- $0
- Enterprise value
- $321.1M
Beyond the preview
Go deeper on Galectin Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Galectin Therapeutics.